Prostate Cancer
Conditions
Keywords
imaging, diagnostic, castration resistant, metastatic prostate cancer, immunotherapy
Brief summary
This study intents to provide an initial evaluation of the utility of positron emission tomography and magnetic resonance (PET/MR) imaging measures for the prediction of immunological response to Sipuleucel T (SipT) therapy.
Detailed description
Recent studies of treatments of prostate cancer through stimulation of adaptive immune response have indicated the linear measurements by computed tomography (CT) and nuclear scans used to assess tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) were inadequate and the value of progression-free survival (PFS) as a predictive surrogate endpoint of survival was lost. The objective of this study is to provide an initial evaluation of the utility of PET/MR imaging measures for the prediction of immunological response to SipT therapy. Investigators expect to identify animaging-signature of response to SipT based on changes in metabolism, perfusion, oxygenation and cellularity of metastasis and its correlation with immunological and clinical response. This approach will help elucidate the mechanism of activity and dynamics of immune antitumor responses to SipT in vivo and to identify new parameters of tumor response and predictive value than current RECIST and PFS standards.
Interventions
DEVICEPET/CT
DEVICEPET/MRI
Sponsors
Dendreon
NYU Langone Health
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men ≥ 18 years of age * History of prostate cancer treated with androgen deprivation * Serum Testosterone levels \<50 ng/mL * Established asymptomatic or minimally symptomatic metastasis * Eastern Cooperative Oncology Group (ECOG) performance status≤2 * Accept the terms of the imaging modalities and performance at pre-established time points as described in the protocol and consent * Accept the terms for immune-monitoring blood drawing and performance at pre-established time points as described in the protocol and consent * Patients that are on steroids (prednisone up to 10mg daily or hydrocortisone 20 mg daily) alone or in combination with Zytega or ketoconazole prior to enrollment are eligible * Patients that are on steroids for an underlying chronic condition are eligible. (prednisone up to 10 mg daily, dexamethasone \<2 mg daily or fludrocortisone 0.1 mg daily orally)
Exclusion criteria
* Chemotherapy or radiation therapy treatment within 21 days of Sipuleucel-T * ECOG performance status \>2 * Prior treatment with Sipuleucel-T * Patients with a history of another primary malignancy within the last 2 years that was not curatively treated, excluding basal or squamous cell carcinoma of the skin * Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required * Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent * Active spinal cord compression.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients with imaging parameter change(s) among the patients with immunological response | up to 14 weeks | NaF-PET/CT, FDG-PET/MRI, and blood drawing (for immunological response) are performed on patients at baseline, day 7 after the last SipT infusion, and week 10 after the last SipT infusion. The changes in SUV (standard uptake value) max on FDG-PET and NaF-PET, in MRI-ADC (apparent diffusion coefficient ) value, in MRI contrast enhancement, and in T2 lesion size will be measured. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients with imaging parameter change(s) among the patients who respond per Response Evaluation Criteria In Solid Tumors (RECIST) | up to 14 weeks | NaF-PET/CT, FDG-PET/MRI, and blood drawing (for immunological response) are performed on patients at baseline, day 7 after the last SipT infusion, and week 10 after the last SipT infusion. The changes in SUV max on FDG-PET and NaF-PET, in MRI-ADC value, in MRI contrast enhancement, and in T2 lesion size will be measured. |
Countries
United States
Outcome results
None listed